Share Name Share Symbol Market Type Share ISIN Share Description
Arthro Kinetics LSE:AKI London Ordinary Share GB00B0XQ4466 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 0.10p 0.00p 0.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown - - - - 0.09

Arthro Kinetics Share Discussion Threads

Showing 451 to 474 of 475 messages
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
DateSubjectAuthorDiscuss
29/9/2008
21:54
http://www.advfn.com/p.php?pid=staticchart&s=L%5Ehbos&p=0&t=1
ameer
01/5/2008
22:00
Well what about that then boys and girls, no big stars, boring if you're not a fan but a European final, well done to the famous Glasgow Rangers....... I know all you tims will be happy for me............
darkside
07/11/2007
09:03
By jove the market likes this news. FDA approval. http://www.advfn.com/p.php?pid=nmona&cb=1194426120&article=23125822&symbol=L%5EAKI
hugepants
18/9/2007
11:19
interims:http://www.investegate.co.uk/Article.aspx?id=200709180701219949D Its an improvement and there are some promising bits but it looks like they'll need more cash soon. Cash minus debt is very low.
hugepants
27/7/2007
14:23
Medtronic to acquire Kyphon for $3.9 billion Medtronic's spinal focus has been on providing treatment options for younger patients who are suffering from scoliosis and degenerative disc disease in the cervical and lumbar spine. It primarily serves orthopedic and neurological surgeons who specialize in spinal surgery. Kyphon's focus has been on treating older patients suffering from vertebral compression fractures and spinal stenosis. Joanne Wuensch, an analyst with BMO Capital Markets, said in a research report, "We believe that this acquisition is an excellent fit for Medtronic, combining leading technology, a rapidly growing top line, a top-notch sales presence, and creating a stronghold in the spinal industry." http://biz.yahoo.com/rb/070727/kyphon_medtronic.html?.v=7
warrantbuyer
29/6/2007
08:30
Market isnt too pleased so far. Agree interims should give clearer picture http://www.investegate.co.uk/Article.aspx?id=200706290701042726Z
hugepants
29/6/2007
07:31
Yes, but on first reading it seems all a bit too historical. Certainly heavy going. Will have another go later, but it may take the next interims (within the next 3 months) to get a proper picture of where thier tradng/finances are now, post the re-financing...
katylied
29/6/2007
07:24
katie - you got your reality check :(
twosmiles
21/6/2007
10:06
A few more buys and we will be back to last weeks level.Anyone thinking of selling hold on as long as you can to get the best price.
oracle5
21/6/2007
08:46
The run up to results and the results will push the price back up to and above the 20 pence level.The pull back in price last week was on very low volume and the price was rising on very small buys.
oracle5
21/6/2007
08:12
Finals by the end of this month (6month period is up). Those numbers should provide a reality check...
katylied
21/6/2007
08:04
More buying today very early in the day.Looking to top up before the next move up.
oracle5
13/6/2007
12:51
Arthro Kinetics European Patent RNS Number:2927Y Arthro Kinetics plc 13 June 2007 Press Release Arthro Kinetics plc - granted European patent WEDNESDAY, 13th June 2007 - Arthro Kinetics plc (AIM: AKI) ("Arthro Kinetics"), the orthopedics company dedicated to regenerating joint mobility and spinal disc function, announces that its wholly owned subsidiary Arthro Kinetics AG has been granted a European patent (EP 1 289 574) for "Cartilage Replacement and Methods for the Production Thereof". Jason Loveridge, CEO of Arthro Kinetics commented: "This is excellent news for Arthro Kinetics and validation of the novelty of our R&D and product portfolio for cartilage regeneration. This patent extends coverage for our core proprietary technology - from which our first product CaReS(R) emerged onto the market in 2003 - to an additional 19 European countries beyond Germany, where the original application was filed in May 2001. We are continuing to pursue protection across all key commercial markets and, in this respect, the European patent represents an important piece of intellectual property protecting our core technology and portfolio of products for cartilage regeneration". END Contact Jason Loveridge Tel: +49 (0)711 305 110 70 Chief Executive, Arthro Kinetics plc
hopestaruk
11/6/2007
13:20
It looks like someone is buying in 50,000 chunks
hugepants
08/6/2007
08:46
This looks like a rise up to possible resistance at 22 pence is now on the cards as it does not take much buying to move the price.
oracle5
07/6/2007
12:15
Up 2p today on this news Expands Chinese Agreement http://www.investegate.co.uk/Article.aspx?id=200706070700409213X
hugepants
05/6/2007
08:58
Sounds promising Japan Licence Agreement http://www.investegate.co.uk/Article.aspx?id=200706050831037735X
hugepants
05/6/2007
08:22
Looks like you've done it agin huge
5dally
04/6/2007
12:10
Yeah Ive no doubt theres been some cash burn. Im not prepared to take a 100% hit though so Ill see what the next results bring. I think their technology should have value; they seem to have chucked a lot of cash developing/marketing it. And its rare just now to see biotechs trading at around cash value. When Ive bought previously at this kind of valuation Ive done pretty well ie. Aortech and more recently Asterand.
hugepants
04/6/2007
10:27
Always a good sign when Huge arrives looking for value. But caution Huge. AKI spend alot on trying to shift their product. I doubt £6m is still left...
katylied
04/6/2007
09:38
I bought some of these a few weeks back. Market cap £7.5M, cash £6M. A bit of a punt but risk/reward looks pretty good.
hugepants
07/4/2007
20:47
Are these a takeover target ? Some large director purchases?
tony979
07/4/2007
07:16
Telegraph: Knee implant offers hope for cartilage repair By Katherine Griffiths Last Updated: 10:19pm BST 06/04/2007 A small orthopaedics company has developed a product which can be implanted into the knee to encourage the body to repair or grow more cartilage. Arthro Kinetics, which is based in Germany and listed in London, said pigs had responded well to its new device. The company aims to have the product approved and on the market by the end of the year. Orthopaedics companies are trying to develop devices which can be implanted in patients who are still quite active to delay or put off completely the need for a metal joint replacement. Modern hip and knee replacements on the market require patients to go to hospital to have cells removed from their joints. These are then grown in a laboratory for several weeks before being injected back into the body as part of the replacement device. Arthro hopes to simplify the process. It is working on a product which would not require patients to go to hospital for the initial removal of cells. Instead, a collagen product would be implanted in the knee which would be able to encourage cells to grow more cartilage. It is also working on a version for ankles. Jason Loveridge, chief executive of Arthro, said cutting out the need for the initial biopsy would make the process easier for the patient and would also cut the cost to health services. "You wouldn't have to see the doctor twice. You also wouldn't require culturing, which needs a building and scientists, and the biopsy is not sterile so there is a risk of infection." Joint replacements have been a big growth area in Europe and the US as people have been living longer and getting fatter. One area companies have been working in is creating devices using the patient's own cells to encourage cartilage to grow again. The National Institute for Clinical Excellence is waiting to see how effective modern joint replacements or enhancements are before making them widely available on the NHS. http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2007/04/07/cnarthro07.xml
jonwig
27/3/2007
15:22
Basically, the share is now down to cash-value. Historic cash-burn has however been high, so could yet see a discount to cash, if good news proves elusive. At this point some very carefull analysis of 2007 trading prospects is required. How much cash out, and how much in... Any volunteers?...
katylied
Chat Pages: 19  18  17  16  15  14  13  12  11  10  9  8  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20161209 19:25:02